Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis.
about
TMC207 for treatment of people with pulmonary tuberculosisFluoroquinolones for treating tuberculosis (presumed drug-sensitive)TMC207: the first compound of a new class of potent anti-tuberculosis drugsCombating Tuberculosis Infection: A Forbidding ChallengeEmerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?Bedaquiline: a review of human pharmacokinetics and drug-drug interactionsRising to the challenge: new therapies for tuberculosisRapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamideMycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosisA new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosisBedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.Recent advances in tuberculosis: New drugs and treatment regimens.Understanding pharmacokinetics to improve tuberculosis treatment outcome.Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.Newer antibacterial drugs for a new century.Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism.Epidemiology and treatment of multidrug resistant tuberculosisClinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis.A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant TuberculosisNew drugs to treat multidrug-resistant tuberculosis: the case for bedaquilineEarly bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patientsPopulation pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug.Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery.Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials.Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs.The challenge of new drug discovery for tuberculosis.Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosisUrine lipoarabinomannan to monitor antituberculosis therapy response and predict mortality in an HIV-endemic region: a prospective cohort study.Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis.Current development and future prospects in chemotherapy of tuberculosisSafety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.Serodiagnosis efficacy and immunogenicity of the fusion protein of Mycobacterium tuberculosis composed of the 10-kilodalton culture filtrate protein, ESAT-6, and the extracellular domain fragment of PPE68.Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometryTuberculosis drug development: ensuring people living with HIV are not left behind.Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings.Targeting bacterial membrane function: an underexploited mechanism for treating persistent infectionsA time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture
P2860
Q24199155-EE6FFB49-1688-42E7-A397-D74706B98D67Q24202081-A96D38BA-24F0-41A7-A3A2-B64AEB36BBE4Q24632091-F753CD8A-8099-480D-A437-055251539DFBQ26750683-FF9CEC65-BEB1-4E91-8B0E-66A196BE7EF7Q26771997-E893D48E-4132-4649-8676-3F42E826EBA8Q26824413-C69AA4C7-40E5-4C0C-974A-FD93F98FEADEQ26864991-AADB8CA4-81D0-417D-AC30-ACB16DFF0BB9Q27011672-3C9411EC-5A96-4D4C-9E70-E1B090D28874Q28478966-237C5E50-8B08-4E57-937A-18E469489911Q28537839-FD90D3A6-4A7C-4DF3-BED0-263EE92CDDEDQ28602112-468FF2FA-FDE1-4DEB-B320-54E8D30A2175Q28659633-2175A774-4FAA-4535-BB51-279336A83FFFQ30249515-EDA4DB85-F761-4936-9C9C-D889BFDE8C9DQ30360811-5EC6D545-6B4B-4013-BB36-97D5E998467DQ30411703-70069A61-4FBF-47D0-97DF-CE9316B9F6FCQ30419537-FCBB1636-E9B9-47A3-A6CF-C73079FB1407Q30433333-4ACBE326-D471-446D-B4F0-E1FAF9F498EAQ30573771-DF2B94AC-BEBA-4993-950B-BCAF40F9A8F0Q33710690-61EDB473-08BC-4179-9387-1E75825163D0Q33760793-24BE6AFC-8BEB-4144-893C-4D6CE0ADFD36Q33939074-9BCCF202-316F-476E-8733-431EDA477D4AQ34005593-7EF4C402-C2E4-410C-AFAC-CA695BDC0C12Q34045233-AE8B7614-918B-46E6-B5D7-F51374348162Q34057390-A28817FB-5173-4110-B3BA-8E9E00945910Q34410451-B7B3D2A4-234D-46FC-8566-235D55847003Q34433240-3D1DAF68-6519-46F4-A6AB-089A22291A6CQ34483596-23149677-7E10-4375-A795-68019958B563Q34660424-B2CC1514-7B34-478E-B642-820D765EC64BQ35031351-D9BE88FC-9AFF-4E0E-BA49-A8869EBE69E1Q35466103-99637EC6-4E55-4FB4-A0EB-8EAD59F09DBFQ35607808-BA3538B5-0C43-4C4F-8DA2-C653EA292B36Q35705874-8C673D56-005E-4D79-A5AC-A1F8E61114CEQ35827839-E3B4A620-FC00-4C46-96C0-10A0FE9F3FADQ35867222-2EA04018-E0B6-4EA1-AC94-16B7D984BD4FQ35960935-CCC849D1-FC54-49B2-9348-9369877D8581Q35991204-A2E66F5F-1AD0-42DA-95E2-24F8B8E86052Q36018942-9668E32A-BF47-4703-8BD7-E10C9AF55402Q36118822-090C6FEF-8F4C-4A9C-A559-5E419C3569B4Q36393640-055771AE-90DB-4170-9D27-356FC6792419Q36558478-EDD9A59E-2A39-4E12-AF86-51FF31243891
P2860
Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Early bactericidal activity an ...... ent of pulmonary tuberculosis.
@ast
Early bactericidal activity an ...... ent of pulmonary tuberculosis.
@en
type
label
Early bactericidal activity an ...... ent of pulmonary tuberculosis.
@ast
Early bactericidal activity an ...... ent of pulmonary tuberculosis.
@en
prefLabel
Early bactericidal activity an ...... ent of pulmonary tuberculosis.
@ast
Early bactericidal activity an ...... ent of pulmonary tuberculosis.
@en
P2093
P2860
P356
P1476
Early bactericidal activity an ...... ent of pulmonary tuberculosis.
@en
P2093
A H Diacon
D F McNeeley
K De Beule
P R Donald
R F Patientia
R Kerstens
P2860
P304
P356
10.1128/AAC.01204-07
P407
P577
2008-05-27T00:00:00Z